Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Emtricitabine/tenofovir alafenamide in HIV infection: added benefit not proven

2016-08-15 Partly no data were available, partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group.  read more Link to "Emtricitabine/tenofovir alafenamide in HIV infection: added benefit not proven"

Adaptive pathways: EMA still leaves open questions unanswered

2016-08-09 The current EMA report on the pilot project again documents the perplexity regarding the use of real world data. Neither EMA nor industry seems to have a conclusive concept.  read more Link to "Adaptive pathways: EMA still leaves open questions unanswered"

Brivaracetam in epilepsy: added benefit still not proven

2016-08-04 The indirect comparison later submitted in the commenting procedure is methodologically better and covers more outcomes than the previous ones. However, an added benefit still cannot be derived.  read more Link to "Brivaracetam in epilepsy: added benefit still not proven"

Afatinib in advanced squamous cell carcinoma of the lung: added benefit not proven

2016-08-01 Neither the direct nor the indirect comparison conducted by the drug manufacturer allows conclusions on advantages or disadvantages in comparison with the appropriate comparator therapy.  read more Link to "Afatinib in advanced squamous cell carcinoma of the lung: added benefit not proven"

Ramucirumab in stomach cancer: added benefit not proven

2016-08-01 Both studies submitted were unsuitable for the assessment of an added benefit because they did not meet the specifications on the comparator therapy and on the target population.  read more Link to "Ramucirumab in stomach cancer: added benefit not proven"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
D15-02 Measurement of myocardial fractional flow reserve (FFR) in coronary heart disease on the preliminary report 2016-09-22
N14-02 Systemic therapy in adults as a psychotherapeutic approach on the preliminary report 2016-09-20

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Nivolumab (Opdivo) for advanced non-small cell lung cancer

The drug nivolumab (trade name: Opdivo) has been approved in Germany since July 2015 for the treatment of advanced lung cancer. It is an option for adults with advanced non-small cell carcinoma who have already had chemotherapy.  read more (Link to "Nivolumab (Opdivo) for advanced non-small cell lung cancer" – opens in a new window)

to top

Glossary entries